Photo of Cindy  Bott, Ph.D.Photo of Cindy  Bott, Ph.D.

Cindy Bott, Ph.D.



University of Cincinnati College of Law, J.D.
  • Order of the Coif; Dean’s Honor List; Charles A. Corry Prize for Corporate Law; West Publishing Prize for Civil Procedure; Timothy Walker Founder's Scholarship (Full Merit Scholar)
  • University of Cincinnati Law Review, Student Articles Editor (1998-1999) and Associate Member (1997-1998)
University of Michigan, Ph.D.
  • Cellular and Molecular Biology
  • Regents Fellowship; Cancer Center Fellowship; Abraham H. Grant Scholastic Award
Michigan State University, B.S.
  • Biochemistry
  • with high honors

Prior Employment

  • Brinks Hofer Gilson & Lione, Counsel, Ann Arbor, MI, 2007-2009
  • Pfizer Inc., Corporate Counsel, Ann Arbor, MI, 2002-2007
  • Procter & Gamble, Counsel, Cincinnati, OH, 1999-2002
  • Institute of Cancer Research, Chester Beatty Laboratories, Postdoctoral Fellow, London England, 1992-1995

Bar Admissions

Court Admissions

Professional Affiliations

American Bar Association

American Intellectual Property Law Association

Intellectual Property Owners Association


Women in Bio

News & Resources


Dr. Bott focuses her practice on the biotechnology and pharmaceutical industries advising clients on a wide range of intellectual property issues. She helps clients to obtain robust patents in the United States and worldwide, and to develop effective global patent strategies. She possesses a technical background in biochemistry, cell biology, molecular biology and immunology, and has extensive in-house experience as patent counsel for Pfizer and Procter & Gamble Pharmaceuticals.  

  • Holds Ph.D. in Cell and Molecular Biology from the University of Michigan
  • Prosecutes global intellectual property portfolios
  • Manages global patent portfolios and provides patent filing strategies
  • Counsels large and small companies regarding product life-cycle management and freedom-to-operate
  • Advises clients regarding Hatch-Waxman issues such as Orange Book listings and patent term extension
  • Negotiates, drafts and reviews agreements related to intellectual property transactional matters
  • Advises and helps position small companies for partnering with large biotech and pharmaceutical companies
  • Renders legal opinions on patent validity and/or patent non-infringement
  • Conducts intellectual property due diligence for transactional matters


  • Obtained numerous U.S. Patents, including:
    • U.S. Patent No. 8,080,567: EP2 receptor agonists
    • U.S. Patent No. 7,189,689: Apolipoprotein A-1 agonists and their use to treat dyslipidemic disorders
    • U.S. Patent No. 7,045,653: Neural endopeptidase inhibitors
    • U.S. Patent No. 6,773, 896: Method for direct measurement of coagulation factor VIIa activity in plasma
    • U.S. Patent No. 6,750,194: Methods of identifying compounds for regulating muscle Mass or function using vasoactive peptide receptors
    • U.S. Patent No. 6,723,499: Method for identifying inhibitors of dual substrate enzymes
    • U.S. Patent No. 6,670,140: Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
    • U.S. Patent No. 6,469,000: 1,3-diheterocyclic metalloprotease inhibitors 
    • U.S. Patent No. 6,316,207: Mouse cardiac muscle cell line HL-1
    • U.S. Patent No. 6,248,554: DNA sequence coding for a BMP receptor
    • U.S. Patent No. 6,225,483: Medium chain length PHA copolymer and process for producing same
    • U.S. Patent No. 6, 162,818: 2-imidazolinylaminoindole compounds useful as alpha-2adrenoceptor agonists
    • U.S. Patent No. 6,117,871: 6-(2-imidazolinylamino) quinoxaline compounds useful as alpha-2adrenoceptor agonists
  • Prosecuted numerous patent applications, including:
    • PCT/US2011/067571 (Not yet published): Detection of LCAT activity
    • PCT/US2011/066736 (Not yet published): Method for treating pancreatitis
    • PCT/US2011/035500 (WO 2011/140429): Delivery of cholesteryl ester to steroidogenic tissues
    • PCT/US2010/038494 (WO2010/144904): Methods for treating red blood cell dysfunction
    • PCT/US2011/031109 (WO 2011/123856) Neuraminidase inhibitors
    • PCT/US2009/066715 (WO 2010/065819): Method for the treatment of neurodegenerative diseases
    • U.S. Application No. 12/820,752 (US 2010/0261760): EP2 receptor agonists
    • U.S. Application No. 12/865,321 (US 2010/0331410): Biaryl amides
    • U.S. Application No. 13/132,670 (US 2011/0293612): Methods for treating red blood cell dysfunction


Burns Park Foreign Language Initiative, Burns Park Elementary School

  • Board Member

ABA Judicial Intern Opportunity Program

  • Volunteer

News & Resources



Seminars & Events